Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 194-202

  Martinez Cardús, Anna ^a   Martinez Balibrea, Eva ^a   Bandrés, Eva ^b   Malumbres, Raquel ^b   Ginés, Alba ^a   Manzano, José Luís ^a   Taron, Miquel ^a   Garcia Foncillas, Jesús ^b   Abad, Albert ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; FLUOROCHROME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; RNA;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION;

CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; RNA, MESSENGER;

EID: 58149511916     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0659     Document Type: Article

References (50)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
2. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26:3661-78.
3. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.
4. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 1995;97:177-84.
5. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000;35:75-93.
6. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 2004;4 Suppl 1:S37-42.
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
8. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
9. Rakitina TV, Vasilevskaya IA, O'Dwyer PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signaling. Cancer Res 2003;63:8600-5.
10. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46.
11. Griffiths GJ, Koh MY, Brunton VG, et al. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 2004;279:46113-21.
12. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003;39:112-9.
13. Samimi G, Manorek G, Castel R, et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 2005;55:1-11.
14. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
15. Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, et al. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 2007;17:637-45.
16. Martinez-Balibrea E, Abad A, Aranda E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 2008;44:1229-37.
17. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006;234:34-9.
18. Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006;29:225-35.
19. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
20. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54.
21. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375-80.
22. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002;32 Suppl:490-5.
23. Dobbin K, Shih JH, Simon R. Questions and answers on design of dual-label microarrays for identifying differentially expressed genes. J Natl Cancer Inst 2003;95:1362-9.
24. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386-401.
25. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internalcontrol genes. Genome Biol 2002;3:RESEARCH0034.
26. Boyer J, Allen WL, McLean EG, et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006;66:2765-77.
27. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-208.
28. Perona R, Sanchez-Perez I. Control of oncogenesis and cancer therapy resistance. Br J Cancer 2004;90:573-7.
29. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by β-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 2005;26:1503-12.
30. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4:977-86.
31. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975-87.
32. Piccolo E, Vignati S, Maffucci T, et al. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene 2004;23:1754-65.
33. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007;67:6325-32.
34. Kim E, Chen F, Wang CC, Harrison LE. CDK5 is a novel regulatory protein in PPARγ ligand-induced antiproliferation. Int J Oncol 2006;28:191-4.
35. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J Biol Chem 2004;279:29302-7.
36. Sharma P, Veeranna, Sharma M, et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 2002;277:528-34.
37. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ. Mol Cell Biol 2007;27:803-17.
38. Gupta RA, Dubois RN. Controversy: PPARγ as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002;283:G266-9.
39. Eichele K, Ramer R, Hinz B. Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 2008;27:3032-44.
40. Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBP. Blood 2007;110:4373-84.
41. Biliran H, Jr., Banerjee S, Thakur A, et al. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-κB activity in pancreatic cancer cells. Clin Cancer Res 2007;13:2811-21.
42. Park ES, Choi S, Kim JM, et al. Early embryonic lethality caused by targeted disruption of the TRAF-interacting protein (TRIP) gene. Biochem Biophys Res Commun 2007;363:971-7.
43. Lee SY, Lee SY, Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-κB activation. J Exp Med 1997;185:1275-85.
44. Regamey A, Hohl D, Liu JW, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor κB activation by tumor necrosis factor. J Exp Med 2003;198:1959-64.
45. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
46. Arnold SM, Fessler LI, Fessler JH, Kaufman RJ. Two homologues encoding human UDP-glucose:glycoprotein glucosyltransferase differ in mRNA expression and enzymatic activity. Biochemistry 2000;39:2149-63.
47. Ollendorff V, Noguchi T, deLapeyriere O, Birnbaum D. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ 1994;5:213-9.
48. Snow BE, Krumins AM, Brothers GM, et al. A G protein γ subunit-like domain shared between RGS11 and other RGS proteins specifies binding to Gβ5 subunits. Proc Natl Acad Sci U S A 1998;95:13307-12.
49. Szepetowski P, Ollendorff V, Grosgeorge J, et al. DNA amplification at 11q13.5-q14 in human breast cancer. Oncogene 1992;7:2513-7.
50. Cui Q, Ma Y, Jaramillo M, et al. A map of human cancer signaling. Mol Syst Biol 2007;3:152.